Evaluating the cost-effectiveness of afatinib after platinum-based therapy for the treatment of squamous non-small-cell lung cancer in France
M Pignata, C Chouaid, K Le Lay, L Luciani… - ClinicoEconomics …, 2017 - Taylor & Francis
Background and aims Lung cancer has the highest mortality rate of all cancers worldwide.
Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an …
Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and has an …
Cost-Effectiveness of Afatinib Versus Erlotinib for The Treatment of Squamous Non-Small Cell Lung Cancer in France After A First-Line Platinium Based Therapy
M Pignata, K Le Lay, L Luciani… - Value in …, 2017 - valueinhealthjournal.com
Objectives To assess the cost-effectiveness of afatinib compared to erlotinib for the treatment
of squamous NSCLC after first-line platinum based therapy from the French healthcare …
of squamous NSCLC after first-line platinum based therapy from the French healthcare …
Cost–effectiveness of afatinib and erlotinib as second-line treatments for advanced squamous cell carcinoma of the lung
J Zhu, W He, M Ye, J Fu, YB Chu, YY Zhao… - Future …, 2018 - Future Medicine
Aim: To investigate the cost–effectiveness of afatinib and erlotinib as second-line therapy for
advanced squamous cell carcinoma of the lung. Materials & methods: A decision-analytic …
advanced squamous cell carcinoma of the lung. Materials & methods: A decision-analytic …
[HTML][HTML] Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small …
PT Tan, MIA Aziz, F Pearce, WT Lim, DBC Wu, K Ng - BMC cancer, 2018 - Springer
Background Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …
Cost-effectiveness analysis of EGFR mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in China
R You, J Liu, DBC Wu, XY Qian, B Lyu… - Cancer management …, 2019 - Taylor & Francis
Objective The purpose of this study was to evaluate the cost-effectiveness of the combined
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …
use of afatinib and epidermal growth factor receptor (EGFR) testing versus gemcitabine …
[HTML][HTML] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
L Westerink, JLJ Nicolai, C Samuelsen… - The European Journal of …, 2020 - Springer
Background The therapeutic landscape for non-small-cell lung cancer (NSCLC) patients that
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
have common epidermal growth factor receptor (EGFR) mutations has changed radically in …
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancer
D Isla, J De Castro, O Juan, S Grau… - ClinicoEconomics …, 2016 - Taylor & Francis
Objectives Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are an
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …
established treatment for advanced non-small cell lung cancer (NSCLC) with EGFR …
Cost-effectiveness analysis of afatinib, erlotinib, and gefitinib as first-line treatments for EGFR mutation-positive non-small-cell lung cancer in Ontario, Canada
Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
J Aguilar-Serra, V Gimeno-Ballester… - Expert Review of …, 2022 - Taylor & Francis
Aim To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib,
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …
[HTML][HTML] Prognostic model of survival outcomes in non-small cell lung cancer patients initiated on afatinib: pooled analysis of clinical trial data
AM Hopkins, A Shahnam, S Zhang… - Cancer Biology & …, 2019 - ncbi.nlm.nih.gov
Objective Several predictors of survival have been identified in EGFR-positive non-small cell
lung cancer (NSCLC) patients treated with first generation EGFR inhibitors. Prognostic …
lung cancer (NSCLC) patients treated with first generation EGFR inhibitors. Prognostic …
相关搜索
- cost effectiveness lung cancer
- cost effectiveness therapy for the treatment
- therapy for the treatment lung cancer
- cost effectiveness use of afatinib
- use of afatinib lung cancer
- cost effectiveness gemcitabine cisplatin
- cost effectiveness egfr tkis
- gemcitabine cisplatin lung cancer
- cost effectiveness mutation testing
- mutation testing lung cancer
- budget impact lung cancer
- effectiveness of afatinib cell carcinoma
- cost effectiveness erlotinib for the treatment
- sequential treatment lung cancer
- egfr mutations lung cancer
- afatinib and erlotinib cell carcinoma